The innovative VenaSeal™ closure system delivers immediate and lasting vein closure with its proprietary medical adhesive and a demonstrated 94.6% closure rate at 5 years.1-3LEARN ABOUT VENASEAL
The ClosureFast™ procedure, with its patented overlap design, is the only RFA procedure with published clinical data demonstrating long-term safety and efficacy, with a 91.9% closure rate at 5 years.4-5LEARN ABOUT CLOSUREFAST
Proebstle, TM. The European Multicenter Study on Cyanoacrylate Embolization of Refluxing Great Saphenous Veins without Tumescent Anesthesia and without Compression Therapy. Results presented at: Charing Cross; 2016; London, UK.
Almeida, JI, Jacier, JJ, Mackay, EG, Bautista, C, Cher, DJ and Proebstle, TM. Thirty-Sixth Month Follow-up of First-in-human Use of Cyanoacrylate Adhesive for Treatment of Saphenous Vein Incompetence. J Vasc Surg: Venous and Lymphatic Disorders. 2017. Published Online: 2 June 2017.
Morrison, N. VeClose 5-Year Follow-up Extension Study Results. Presented at Charing Cross 2019; London, UK.
Proebstle TM, Alm BJ, Göckeritz O, et al. Five-year results from the prospective European multicentre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins. Br J Surg. February 2015;102(3):212-218.
ClosureFast and ClosureFast RFS Patents. https://www.medtronic.com/content/dam/medtronic-com/global/Corporate/meaningful-innovation/documents/CVG-Patent-Marking.pdf.pdf